Last reviewed · How we verify
AK112, Cadonilimab, nab-paclitaxel, gemcitabine
CD47 antibody
CD47 antibody Used for Non-small cell lung cancer, Pancreatic cancer.
At a glance
| Generic name | AK112, Cadonilimab, nab-paclitaxel, gemcitabine |
|---|---|
| Sponsor | Akeso |
| Drug class | CD47 antibody |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Cadonilimab is a CD47 antibody that works by binding to CD47 on the surface of cancer cells, thereby blocking its interaction with signal-regulatory protein-alpha (SIRPα) on the surface of immune cells, which leads to the activation of immune cells and the killing of cancer cells.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |